The underlying molecular mechanism of sodium butyrate in preventing hepatic steatosis may be attributed to the activation of CaMKII‐CREB and inhibition of the HDAC1‐CREB signaling pathway via hepatic GPR41/43. The gene discussed is CAMK2G; the disease is Hepatic steatosis.